KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Net Cash Flow (2019 - 2025)

Historic Net Cash Flow for Royalty Pharma (RPRX) over the last 7 years, with Q4 2025 value amounting to -$320.2 million.

  • Royalty Pharma's Net Cash Flow fell 142310.47% to -$320.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$310.3 million, marking a year-over-year decrease of 16865.46%. This contributed to the annual value of -$310.3 million for FY2025, which is 16865.46% down from last year.
  • According to the latest figures from Q4 2025, Royalty Pharma's Net Cash Flow is -$320.2 million, which was down 142310.47% from $307.0 million recorded in Q3 2025.
  • In the past 5 years, Royalty Pharma's Net Cash Flow ranged from a high of $921.6 million in Q2 2024 and a low of -$1.2 billion during Q3 2023
  • Over the past 5 years, Royalty Pharma's median Net Cash Flow value was $178.0 million (recorded in 2023), while the average stood at -$19.5 million.
  • Its Net Cash Flow has fluctuated over the past 5 years, first skyrocketed by 37684.13% in 2022, then crashed by 142310.47% in 2025.
  • Over the past 5 years, Royalty Pharma's Net Cash Flow (Quarter) stood at -$259.8 million in 2021, then surged by 376.84% to $719.1 million in 2022, then tumbled by 163.89% to -$459.4 million in 2023, then skyrocketed by 95.42% to -$21.0 million in 2024, then plummeted by 1423.1% to -$320.2 million in 2025.
  • Its last three reported values are -$320.2 million in Q4 2025, $307.0 million for Q3 2025, and -$455.8 million during Q2 2025.